San Diego, USA — October 9, 2025 — SeekIn Inc., a leading innovator in liquid biopsy-based cancer diagnostics, the publication of the second landmark study on its flagship multi-cancer early detection (MCED) product, OncoSeek®, in npj Precision Oncology.
Groundbreaking Results Confirm OncoSeek® as a Rapid, Cost-Effective Solution for Global Cancer Early Detection
An international, multi-center clinical trial has validated the effectiveness of OncoSeek®, an advanced AI-powered blood test designed for early detection of multiple cancers. The results, featured in npj Precision Oncology, underscore OncoSeek’s promise in transforming cancer screening, notably in low- and middle-income countries (LMICs). The article can be found at https://rdcu.be/eJ0Pq.
Study Highlights
The study involved seven prominent medical centers across Brazil, China, and the United States, enrolling 15,122 participants (including 3,029 cancer patients and 12,093 non-cancer controls). Testing was conducted on four laboratory platforms with both serum and plasma samples.
Key data from the study includes:
- Area under the curve (AUC): 0.829
- Sensitivity: 58.4%
- Specificity: 92.0%
- Tissue-of-origin prediction accuracy: 70.6% (top-two organs in diagnosed cases)
Transformative Potential for Global Oncology
OncoSeek® proved highly effective, detecting 14 major cancer types—including those responsible for over 72% of worldwide cancer mortality, such as lung, liver, colorectal, pancreatic, stomach, and breast cancers. Sensitivity varied from 38.9% to 83.3% depending on cancer type. Notably, OncoSeek® is both affordable (under $25 per test) and rapid (results within 1.5 hours), making it ideal for widespread implementation, even in resource-constrained environments. OncoSeek® is already available in Brazil, Bulgaria, China, Colombia, Mexico, the Netherlands, Nigeria, Pakistan, and Poland.
Leadership Perspective
Dr. Mao Mao, corresponding author, Founder and CEO of SeekIn Inc., stated: “OncoSeek represents a significant advance in global cancer control. Its combination of speed, affordability, and broad cancer panel coverage, enabled by AI and commonly available laboratory equipment, positions it to extend life-saving early cancer detection to the populations that need it most.”
Looking Ahead
Study authors recommend the adoption of OncoSeek® as a frontline MCED tool while calling for more large-scale prospective studies, particularly to confirm benefits in early-stage cancer detection.